SPRINT System is the least invasive PNS device for CRPS
CLEVELAND, Nov. 15, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced that Marc Huntoon, M.D. of VCU Medical Center was the first to use the recently FDA-cleared SPRINT endura™ single-lead Peripheral Nerve Stimulation (PNS) System, for the treatment of complex regional pain syndrome, or CRPS.
Complex regional pain syndrome (CRPS) is a debilitating, chronic pain condition affecting the limbs that can be induced by surgery, trauma or injury. While CRPS can be very difficult to treat, earlier intervention has been shown to improve outcomes, and PNS can be an effective option. Historically, PNS involved an invasive neurosurgical procedure, and as a result it was not often considered as an early treatment option. The SPRINT system is a minimally invasive PNS option that is conducive to use early in the treatment continuum.
“I have been treating complex regional pain syndrome, a condition known as CRPS, for nearly three decades. In my experience, patients suffering chronic pain benefit from early intervention with peripheral nerve stimulation. Now that there is a less invasive percutaneous option, PNS can more easily be deployed sooner in the care continuum,” said Dr. Marc A. Huntoon, director of pain management at the Neuroscience, Orthopaedic and Wellness Center, a hospital outpatient facility of VCU Medical Center. “In my experience, this new method of peripheral nerve stimulation is generally safe, effective and minimally invasive.” In addition to treating CRPS it has also been helpful in treating other pain conditions such as back pain, shoulder pain, post-amputation pain, and pain following surgery, such as total knee replacement.
“We are pleased to see accelerated adoption of the latest version of our SPRINT Peripheral Nerve Stimulation system following its recent FDA clearance. It is gratifying to see the SPRINT system being prescribed earlier in the disease process for a broad range of pain disorders, including CRPS, due to our technology’s minimally invasive and patient-friendly features,” said Maria Bennett, Founder, President and CEO of SPR Therapeutics, Inc.
About SPRINT® PNS System
The SPRINT Peripheral Nerve Stimulation (PNS) System is the only percutaneous PNS device that is FDA-cleared for both chronic and acute pain, including post-operative and post-traumatic pain. The SPRINT PNS System leads are placed by a physician during an outpatient procedure without surgery, incisions, tissue destruction or anesthesia, and are connected to a wearable stimulator that delivers stimulation for up to 60 days of therapy. The lead is then removed. In multiple studies, the SPRINT system has demonstrated significant and sustained pain relief post-60-day treatment. Physicians have used the SPRINT system to treat post-amputation pain, shoulder pain, lower back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement (partial listing). For additional information regarding safety and efficacy visit www.sprtherapeutics.com.
About SPR Therapeutics, Inc.
SPR Therapeutics, Inc. is a privately-held medical device company headquartered in Cleveland, Ohio, focused on developing, manufacturing and commercializing non-opioid, minimally invasive, treatment options that improve quality of life. The company’s SPRINT technology is the only percutaneous Peripheral Nerve Stimulation (PNS) System FDA-cleared to treat both chronic and acute pain. More information can be found at: www.sprtherapeutics.com.
SPR Contact:
Mark Stultz
Senior Vice President
mstultz@sprtherapeutics.com
612-770-0390
Media Contact:
Helen Shik
Shik Communications LLC
ShikPR@sprtherapeutics.com
617-510-4373